Correlation Between Lipigon Pharmaceuticals and Simris Alg

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lipigon Pharmaceuticals and Simris Alg at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lipigon Pharmaceuticals and Simris Alg into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lipigon Pharmaceuticals AB and Simris Alg AB, you can compare the effects of market volatilities on Lipigon Pharmaceuticals and Simris Alg and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lipigon Pharmaceuticals with a short position of Simris Alg. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lipigon Pharmaceuticals and Simris Alg.

Diversification Opportunities for Lipigon Pharmaceuticals and Simris Alg

0.7
  Correlation Coefficient

Poor diversification

The 3 months correlation between Lipigon and Simris is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Lipigon Pharmaceuticals AB and Simris Alg AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Simris Alg AB and Lipigon Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lipigon Pharmaceuticals AB are associated (or correlated) with Simris Alg. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Simris Alg AB has no effect on the direction of Lipigon Pharmaceuticals i.e., Lipigon Pharmaceuticals and Simris Alg go up and down completely randomly.

Pair Corralation between Lipigon Pharmaceuticals and Simris Alg

Assuming the 90 days trading horizon Lipigon Pharmaceuticals AB is expected to under-perform the Simris Alg. In addition to that, Lipigon Pharmaceuticals is 1.02 times more volatile than Simris Alg AB. It trades about -0.02 of its total potential returns per unit of risk. Simris Alg AB is currently generating about -0.01 per unit of volatility. If you would invest  30.00  in Simris Alg AB on September 4, 2024 and sell it today you would lose (22.28) from holding Simris Alg AB or give up 74.27% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Lipigon Pharmaceuticals AB  vs.  Simris Alg AB

 Performance 
       Timeline  
Lipigon Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lipigon Pharmaceuticals AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Simris Alg AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Simris Alg AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's forward indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Lipigon Pharmaceuticals and Simris Alg Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lipigon Pharmaceuticals and Simris Alg

The main advantage of trading using opposite Lipigon Pharmaceuticals and Simris Alg positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lipigon Pharmaceuticals position performs unexpectedly, Simris Alg can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Simris Alg will offset losses from the drop in Simris Alg's long position.
The idea behind Lipigon Pharmaceuticals AB and Simris Alg AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Complementary Tools

Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Stocks Directory
Find actively traded stocks across global markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm